{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:52:26Z","timestamp":1769125946547,"version":"3.49.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ershiyiwei Lvronghao Concentrated Pills (ESYWLRHW) is the concentrated pill developed and prepared based on the classical prescription in Xizang: Ershiwuwei Lvronghao Pills (ESWWLRHW). However, its effect on nonalcoholic fatty liver disease (NAFLD) remains unclear. The aim of this study is to clarify the therapeutic effect and mechanism of ESYWLRHW on NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>High-Performance Liquid Chromatography-Quadrupole Time of Flight-Mass Spectrometry\/Mass Spectrometry (HPLC-Q-TOF-MS\/MS) was used to analyze the components of ESYWLRHW. The NAFLD model was established by feeding Sprague-Dawley (SD) rats with high-fat diet (HFD) for ten consecutive weeks, and different doses of ESYWLRHW and positive drugs were given for intervention treatment in the last 6\u00a0weeks. The pathological and molecular changes of rats in each group were determined after the whole experimental procedure with pathological sections and ELISA experiments, and the metabolomics, proteomics and transcriptomics were used to investigate the possible mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this study, 206 compounds of ESYWLRHW were identified.\n                      <jats:italic>In vivo<\/jats:italic>\n                      experiments, ESYWLRHW administration significantly ameliorated the pathological manifestations in NAFLD model rats, including attenuating the abnormal body weight gain, reducing the accumulation of hepatic and peripheral fat, and improving dyslipidemia, liver function, and systemic inflammatory response. Metabolomic analysis further revealed that ESYWLRHW treatment upregulated the levels of specific metabolites, such as 12-keto-leukotriene B4 (12-keto-LTB4), 20-COOH-LTB4, glycocholate (GCA), and dehydroepiandrosterone sulfate (DHEAS). Integrated multi-omics analysis and subsequent verification indicated that the therapeutic effects of ESYWLRHW might be mediated by modulating the expression of Peroxisome Proliferator-Activated Receptors (PPARs), which in turn regulated downstream signaling pathways including nuclear factor erythroid 2-related factor 2 (Nrf2) and the Nuclear Factor-kappa B (NF-\u03baB)\/NOD-like receptor family, pyrin domain-containing 3 (NLRP3)\/Caspase-1 axis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, ESYWLRHW can regulate the three metabolic pathways: arachidonic acid metabolism, primary bile acid biosynthesis and steroid hormone biosynthesis, and improve oxidative stress and inflammation in NAFLD rats by regulating the expression of PPARs protein, and ultimately alleviate NAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1725610","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:53:47Z","timestamp":1769064827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Study on the effect and mechanism of Ershiyiwei Lvronghao concentrated Pills in the treatment of nonalcoholic fatty liver disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Yexin","family":"Wu","sequence":"first","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintao","family":"Long","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxin","family":"Pai","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Medical College of Xizang University","place":["Lhasa, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Translational Medicine for Human Adaptation to the High-Altitude of Xizang Autonomous Region, High Altitude Medical Research Institute, Xizang Autonomous Region People\u2019s Hospital","place":["Lhasa, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengui","family":"Ye","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University","place":["Chengdu, China"]},{"name":"Medical College of Xizang University","place":["Lhasa, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/s1043-2760(02)00617-3","article-title":"DHEA treatment: myth or reality?","volume":"13","author":"Allolio","year":"2002","journal-title":"Trends Endocrinol. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13643","article-title":"Global epidemiology of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: what we need in the future","volume":"38","author":"Ara\u00fajo","year":"2018","journal-title":"Liver Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0009920","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol. Cell. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1006\/bbrc.1993.1378","article-title":"PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene","volume":"192","author":"Bardot","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B5","first-page":"4","article-title":"Determination of hydroxysafflor yellow A in Ershiwuwei Lvronghao pills by HPLC","volume":"27","author":"Basang","year":"2018","journal-title":"Chin. J. Etnmed. Etnpharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B8","first-page":"1458","article-title":"Analysis of aristolochic acid A in Ershiwuwei Luronghao pills","volume":"29","author":"Chen","year":"2009","journal-title":"Chin. J. Pharm. Anal."},{"key":"B9","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets","volume":"245","author":"Chen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1164\/rccm.200907-1047OC","article-title":"Nrf2-regulated PPAR\u03b3 expression is critical to protection against acute lung injury in mice","volume":"82","author":"Cho","year":"2010","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"32681","DOI":"10.1074\/jbc.M002577200","article-title":"Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B","volume":"275","author":"Chung","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1161\/CIRCRESAHA.108.188771","article-title":"Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes","volume":"104","author":"Collins","year":"2009","journal-title":"Circ. Res."},{"key":"B13","volume-title":"The Ministry of Health of the People 's Republic of China Drug Standards (Tibetan medicine first)","author":"Commission","year":"1995"},{"key":"B14","first-page":"1663","article-title":"Sex hormones in postmenopausal HLA-identical rheumatoid arthritis discordant sibling pairs","volume":"19","author":"Deighton","year":"1992","journal-title":"J. Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jceh.2015.02.006","article-title":"Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the liver, Endocrine Society of India, Indian college of Cardiology and Indian Society of gastroenterology","volume":"5","author":"Duseja","year":"2015","journal-title":"J. Clin. Exp. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"156395","DOI":"10.1016\/j.phymed.2025.156395","article-title":"Qige decoction attenuated non-alcoholic fatty liver disease through regulating SIRT6-PPAR\u03b1-mediated fatty acid oxidation","volume":"138","author":"Fan","year":"2025","journal-title":"Phytomedicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17878","DOI":"10.1038\/srep17878","article-title":"Erythropoietin alleviates hepatic insulin resistance via PPAR\u03b3-dependent AKT activation","volume":"5","author":"Ge","year":"2015","journal-title":"Sci. Rep."},{"key":"B22","first-page":"102","article-title":"Study on the anti-inflammatory mechanism of glycocholic acid","author":"Guan","year":"2009","journal-title":"Heilongjiang Anim. Sci. Vet. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"15489","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"156654","DOI":"10.1016\/j.phymed.2025.156654","article-title":"Linghe granules reduces hepatic lipid accumulation in Non-alcoholic fatty liver disease through regulating lipid metabolism and redox balance","volume":"141","author":"Hu","year":"2025","journal-title":"Phytomedicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"155229","DOI":"10.1016\/j.phymed.2023.155229","article-title":"Preventive mechanisms of Chinese Tibetan medicine Triphala against nonalcoholic fatty liver disease","volume":"123","author":"Jiang","year":"2024","journal-title":"Phytomedicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26599\/fshw.2024.9250446","article-title":"A new synbiotic supplementation ameliorates ulcerative colitis via modulating microbial homeostasis, protecting intestinal barrier integrity, and maintaining immunity homeostasis in mice","author":"Kang","year":"2025","journal-title":"Food Sci. Hum. Welln."},{"key":"B29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1530\/eje.0.1450457","article-title":"Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women","volume":"145","author":"Lasco","year":"2001","journal-title":"Eur. J. Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-kappaB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B31","first-page":"2006","article-title":"Studies on anti-inflammatory effects and its mechanisms of glycocholic acid","author":"Li","year":"2006","journal-title":"Inn. Mong. Agr. U."},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jare.2024.03.004","article-title":"Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: a review","volume":"68","author":"Li","year":"2024","journal-title":"J. Adv. Res."},{"key":"B33","first-page":"1202","article-title":"Study on preparation technology and pharmacokinetics of glycocholic acid sustained-release pellets","volume":"56","author":"Li","year":"2025","journal-title":"Chin. Tradit. Herb. Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.13422\/j.cnki.syfjx.20241016","article-title":"Mechanism of yantiao prescription in treating lipopolysaccharide-induced acute lung injury based on arachidonic acid metabolic pathways","volume":"31","author":"Li","year":"2025","journal-title":"Chin. J. Exp. Tradit. Med. Form."},{"key":"B35","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.3390\/ijms26178568","article-title":"The sex hormone precursors dehydroepiandrosterone (DHEA) and its sulfate ester form (DHEAS): molecular mechanisms and actions on human body","volume":"26","author":"Lin","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"901","DOI":"10.13429\/j.cnki.cjcr.2024.06.017","article-title":"Correlation between serum manganese and non-alcoholic fatty liver disease","volume":"37","author":"Liu","year":"2024","journal-title":"Chin. J. Clin. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/s0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo. Clin. Proc."},{"key":"B38","doi-asserted-by":"publisher","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"8298","DOI":"10.3390\/ijms22158298","article-title":"PPARs as metabolic sensors and therapeutic targets in liver diseases","volume":"22","author":"Monroy-Ramirez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1172\/JCI119715","article-title":"Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling","volume":"100","author":"Peraldi","year":"1997","journal-title":"J. Clin. Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0026-0495(91)90172-s","article-title":"Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index","volume":"40","author":"Pergola","year":"1991","journal-title":"Metabolism"},{"key":"B44","first-page":"1105","article-title":"Body fat accumulation is possibly responsible for lower dehydroepiandrosterone circulating levels in premenopausal obese women","volume":"20","author":"Pergola","year":"1996","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/s0022-3565(25)12349-5","article-title":"Effects of metabolites of leukotriene B4 on human neutrophil migration and cytosolic calcium levels","volume":"276","author":"Powell","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/carcin\/19.6.999","article-title":"Identification of dithiolethione-inducible gene-1 as a leukotriene B4 12-hydroxydehydrogenase: implications for chemoprevention","volume":"19","author":"Primiano","year":"1998","journal-title":"Carcinogenesis"},{"key":"B47","first-page":"481","article-title":"Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone","volume":"51","author":"Ratko","year":"1991","journal-title":"Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.freeradbiomed.2013.08.174","article-title":"Free radical biology for medicine: learning from nonalcoholic fatty liver disease","volume":"65","author":"Serviddio","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/toxsci\/kfn142","article-title":"Ligand activation of peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression","volume":"105","author":"Shan","year":"2008","journal-title":"Toxicol. Sci."},{"key":"B51","first-page":"1095","article-title":"Exploration of the mechanism of liver injury caused by ethanol extract of Inonotus Obliquus based on liver metabolomics","volume":"40","author":"Shen","year":"2024","journal-title":"J. Chang. U. Chin. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1055\/s-0029-1211136","article-title":"Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress","volume":"99","author":"Stahl","year":"1992","journal-title":"Exp. Clin. Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"159571","DOI":"10.1016\/j.bbalip.2024.159571","article-title":"Age-dependent changes in visceral adiposity are associated with decreased plasma levels of DHEA-S in sigma-1 receptor knockout male mice","volume":"1870","author":"Stelfa","year":"2025","journal-title":"Biochim. Biophys. Acta. Mol. Cell. Biol. Lipids"},{"key":"B54","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/0026-0495(95)90060-8","article-title":"Reduced testosterone and adrenal C19 steroid levels in obese men","volume":"44","author":"Tchernof","year":"1995","journal-title":"Metabolism"},{"key":"B56","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s0022-3565(25)24038-1","article-title":"Stereochemical analysis and biological activity of 3-hydroxy-leukotriene B4: a metabolite from ethanol-treated rat hepatocytes","volume":"271","author":"Wheelan","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3892\/etm.2023.11931","article-title":"The hepatoprotective effect of aspirin on carbon tetrachloride-induced hepatic fibrosis via inhibition of TGF\u03b2-1 pathway and pro-inflammatory cytokines IL-1\u03b2 and COX-2 in rats","volume":"25","author":"Wu","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"B58","first-page":"1","article-title":"Research progress of the multi-target anti-inflammatory drugs based on arachidonic acid pathway","author":"Wu","year":"2024","journal-title":"J. China Pharm. U."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1111\/jcmm.15028","article-title":"Therapeutic potential of PPAR\u03b3 natural agonists in liver diseases","volume":"24","author":"Wu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"B60","first-page":"77","article-title":"Effect of glycocholic Acid(GCA)on anti-oxidation capacity of mouse peritoneal macrophages","volume":"41","author":"Wu","year":"2020","journal-title":"Anim. Husb. Feed Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/cells9020352","article-title":"PPAR-mediated toxicology and applied pharmacology","volume":"9","author":"Xi","year":"2020","journal-title":"Cells"},{"key":"B62","doi-asserted-by":"publisher","first-page":"155005","DOI":"10.1016\/j.phymed.2023.155005","article-title":"Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis","volume":"119","author":"Yin","year":"2023","journal-title":"Phytomedicine"},{"key":"B63","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1725610\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:53:51Z","timestamp":1769064831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1725610\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":63,"alternative-id":["10.3389\/fphar.2025.1725610"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1725610","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"1725610"}}